My lab’s vision for the next five years is to apply what we have learned to develop molecules that can alter FA protein behavior. These could be used to treat cancer or alter gene editing outcomes.
Directory
![](https://fanconi.org/wp-content/uploads/2020/07/Sharon_Cantor.jpg)
Sharon Cantor
Associate Professor | PhD
My laboratory focuses on understanding how tumor suppressor proteins function to maintain genomic integrity and suppress cancer. In particular, we focus on the hereditary breast and ovarian cancer genes, BRCA1, BRCA2 and the BRCA1-associated helicase, FANCJ (BACH1/ BRIP1). Bi-allelic loss of these genes also causes Fanconi anemia (FA), a rare chromosomal instability and cancer syndrome. Our work on FANCJ revealed that DNA repair defects underlie both hereditary breast cancer and FA. Currently, we are employing biochemical and whole-genome screening technologies, to uncover mechanisms regulating DNA repair choice and how cancer cells evade toxic chemotherapies.
FA Research Projects
Year | Project |
---|---|
2020 | A small molecule approach to overcome replication dysfunction in FA |
The Latest
News & Events
![](https://fanconi.org/wp-content/uploads/2024/06/IMG_1499s-scaled-e1718991245321-1024x554.jpg)
![](https://fanconi.org/wp-content/uploads/2024/06/Omar7-778x1024.png)
In a world where every day presents new challenges, my 11-year-old son, Omar, from Oman, stands out for his resilience and eagerness to raise awareness about Fanconi anemia. Diagnosed at just five years old, we truly believe his journey is a testament to hope and the strength of the human spirit.
![](https://fanconi.org/wp-content/uploads/2024/04/Copy-of-FCF-Social-Media-Templates-1024x1024.png)
That's why we're thrilled to announce the launch of the Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research, a flagship funding opportunity in partnership with the American Association for Cancer Research (AACR).